H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Werewolf Therapeutics to $15 from $20 and keeps a Buy rating on the shares. Werewolf continues to make progress with its most advanced Indukine candidate WTX-124 with initial interim safety, tolerability and preliminary efficacy data from the monotherapy cohorts of WTX-124×2101 in Q4 of 2023, the analyst tells investors in a research note. The firm says "patience is required" in Werewolf shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HOWL:
- Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Werewolf Therapeutics reports Q4 EPS (39c), consensus (55c)
- UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
- Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
- Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
